aap Implantate sold its biomaterials unit to an undisclosed private equity firm in the EU for €36MM (~US $40.3MM). For 2015, the unit achieved revenue of ~US $17.9MM. Upon closing, which is slated for 2Q16, aap will proceed as a pure-play trauma entity.
aap’s trauma products include a standard osteosynthesis portfolio and LOQTEQ® anatomical locking compression technology. LOQTEQ launched internationally in 2011, and the company received its first FDA 510(k) clearance for a LOQTEQ small fragment plating system in 3Q12. aap also holds IP for a multifunctional antibacterial silver implant coating.
The divested Biomaterials unit is specialized in development, production and marketing of bone substitutes, collagen fleece, cements, mixing systems and related accessories.
Last year at this time, aap Implantate announced that advanced-stage negotiations for sale of this subsidiary were ceased, as final transaction terms and conditions could not be met.
Update 5/11/16: The buyer is Keensight Capital.
aap Implantate sold its biomaterials unit to an undisclosed private equity firm in the EU for €36MM (~US $40.3MM). For 2015, the unit achieved revenue of ~US $17.9MM. Upon closing, which is slated for 2Q16, aap will proceed as a pure-play trauma entity.
aap Implantate sold its biomaterials unit to an undisclosed private equity firm in the EU for €36MM (~US $40.3MM). For 2015, the unit achieved revenue of ~US $17.9MM. Upon closing, which is slated for 2Q16, aap will proceed as a pure-play trauma entity.
aap’s trauma products include a standard osteosynthesis portfolio and LOQTEQ® anatomical locking compression technology. LOQTEQ launched internationally in 2011, and the company received its first FDA 510(k) clearance for a LOQTEQ small fragment plating system in 3Q12. aap also holds IP for a multifunctional antibacterial silver implant coating.
The divested Biomaterials unit is specialized in development, production and marketing of bone substitutes, collagen fleece, cements, mixing systems and related accessories.
Last year at this time, aap Implantate announced that advanced-stage negotiations for sale of this subsidiary were ceased, as final transaction terms and conditions could not be met.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
